EP Patent

EP1711510A4 — THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION

Assigned to Silence Therapeutics PLC · Expires 2008-11-26 · 17y expired

What this patent protects

Patent listed against Lotemax.

Drugs covered by this patent

Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health

Patent Metadata

Patent number: EP1711510A4
Jurisdiction: EP
Classification: —
Expires: 2008-11-26
Drug substance claim: No
Drug product claim: No
Assignee: Silence Therapeutics PLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.